openPR Logo
Press release

Viral Antigens Market to Reap Excessive Revenues by 2028(Based on product type, the global viral antigens market is segmented as: Herpes Simplex Virus (HSV) Viral Antigens Type 1 Antigen Type 2 Antigen Rotavirus Viral Antigens Influenza Viral Antigens)

04-10-2019 09:31 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

Viral Antigens Market to Reap Excessive Revenues by 2028(Based

Antigens are commonly referred to as substances that are capable of triggering an immune response in a host by activating the lymphocytes or initiating antibody production against infections. Depending upon the fact that they either enter the human body or originate within the body, viral antigens are classified as foreign or self-antigens respectively. Among these, self-antigens comprise mutated or overexpressed proteins. However, foreign antigens are likely to include bacteria, parasites, viruses, chemicals and sometimes toxins & proteins found in food products.

Viral antigens, defined as an antigen that contains multiple antigenicity that is protein in nature. These multiple antigenicity present on viral antigens are strain-specific and closely related to the virus particle. Viral antigens are basically protein encoded and specified by the viral genome that can be detected by an explicit immunological response. These highly immunogenic antigenic determinants elicit strong immune responses, owing to which they are used to diagnose various viral infections for clinical research purposes.

Viral antigens in the viral antigens market are majorly found in distinct formats such as purified, inactivated pathogens, cell lysates and antigen carrier conjugates. A wide range of native state viral antigens is highly in demand, particularly for vaccine research and in-vitro diagnostics. Standard properties recommended for apt viral antigens include higher specificity & sensitivity, simple production & quality control, capability of a viral protein to mimic its way into the cells and level of safety in cases of oncogenic viruses. Under the product type segment defined for the viral antigens market, the influenza viral antigens accounts for a significant revenue share in the global viral antigens market followed by the adenovirus viral antigens. Herpes Simplex Virus (HSV) antigen and rotavirus antigen are commonly recommended viral antigens in the viral antigens market to fight various acute diseases such as AIDS, influenza and others. These viral antigens find applications in various diagnostic techniques, which include ELISA, immunodiagnostic assays, and hemagglutination tests, in the viral antigens market. The major potential end users for the viral antigens market, where these antigens are highly in demand and generate significant revenues, include hospitals, associated diagnostic laboratories, diagnostic laboratories & centres and academic & research institutes.

Request Free Sample Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=1305

Viral Antigens Market: Drivers and Restraints

The growing demand for recombinant viral antigens that are capable of producing recombinant viral proteins, thereby ensuring that the ELISAs are safe, specific and rapid, is expected to be among major factors driving the viral antigens market over the forecast period. Moreover, the high capability of viral antigens to reduce the risk of false negatives, growing incidence of acute diseases such as hepatitis, AIDS, cancers & infectious diseases, and increase in diagnostic population for variant diseases is also expected to drive the revenue growth of the global viral antigens market. Approval and launch of new viral antigens is another important factor contributing to the growth of the global viral antigens market. However, increase in the risk of viral infection and safety issues are restraining the revenue growth of the global viral antigens market.

Viral Antigens Market: Segmentation

The global viral antigens market can be segmented on the basis of product type, pathogen type, application, end user and geography.

Based on product type, the global viral antigens market is segmented as:

Herpes Simplex Virus (HSV) Viral Antigens
Type 1 Antigen
Type 2 Antigen
Rotavirus Viral Antigens
Influenza Viral Antigens
Influenza A H1N1 Viral Antigens
Influenza B Viral Antigens
Epstein-Barr Virus Antigens
Hepatitis A-E Virus Antigens
Parainfluenza Virus Antigens
Type 1 Antigen
Type 2 Antigen
Type 3 Antigen
Measles Virus Antigens
Adenovirus Type 2 Hexon Viral Antigens
Mumps/Parotitis Virus Antigens
Varicella Zoster Virus (VZV) Antigens
Cytomegalovirus Antigens
Others
Based on pathogen type, the global viral antigens market is segmented as:

Inactivated Pathogen
Purified Pathogen
Based on application type, the global viral antigens market is segmented as:

ELISA
Immunoassay
Hemagglutination
Others

Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1305

Based on end user, the global viral antigens market is segmented as:

Hospital Associated Diagnostic Laboratories
Diagnostic Laboratories and Centres
Academic and Research Institutes
Viral Antigens Market: Overview

The global viral antigens market is expected to register modest growth over the forecast period due to increase in the incidence of acute life-threatening diseases such as influenza, hepatitis and AIDS, which are among major threats for global public health. A number of viral antigens intended for antibody detection or to be used as a positive control to perform a variety of immunodiagnostic assays such as ELISA are being introduced in the viral antigens market. They are being offered by leading players such as Jena Bioscience GmbH, Biologics International Inc. and Creative Diagnostics. Due to the presence of domestic manufacturers, there is strong competition among domestic and regional players in the viral antigens market. Among the different types of viral antigens indicated for various diagnostic applications, the adenovirus antigen segment is expected to contribute a significant revenue share in the global viral antigens market over the forecast period followed by the influenza antigen product segment. Among the pathogen type segment, inactivated viral pathogen is expected to register substantial demand from diagnostic centres and hospitals as compared to purified pathogens. Diagnostic laboratories and centres, followed by hospital-associated diagnostic laboratories, are expected to contribute a high revenue share in the global viral antigens market as these are the most significant platforms to perform immunodiagnostic tests.

Viral Antigens Market: Regional Outlook

Geographically, the global viral antigens market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). North America is expected to generate the highest revenue in the global viral antigens market owing to the growing prevalence of acute diseases such as HIV AIDS and influenza, thus elevating research applications of viral antigens in the region as compared to other regions. The viral antigens market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the large presence of domestic players that manufacture viral antigens to perform immunoassays and hemagglutination tests on the affected population to diagnose viral infection. Europe is expected to register the second-largest share in the global viral antigens market throughout the forecast period owing to an increase in the presence of viral antigens distributors and suppliers across the region.

Viral Antigens Market: Key Players

The global viral antigens market is highly fragmented owing to the presence of a large number of domestic manufacturers. Some of the key players operating in the global viral antigens market are Bio Rad Laboratories, Inc.; Creative Diagnostics; Viral Antigens, Inc.; The Native Antigen Company Ltd.; Jena Bioscience GmbH; GenScript Corporation; Aalto Bio Reagents and Advanced Biotechnologies Inc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
CIS & Russia
Japan
APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)
Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Report Analysis@ https://www.factmr.com/report/1305/viral-antigens-market

About US
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - http://theguardiantribune.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Viral Antigens Market to Reap Excessive Revenues by 2028(Based on product type, the global viral antigens market is segmented as: Herpes Simplex Virus (HSV) Viral Antigens Type 1 Antigen Type 2 Antigen Rotavirus Viral Antigens Influenza Viral Antigens) here

News-ID: 1696930 • Views: 241

More Releases from Fact.MR

Sales of Robot Vision System Is Expected To Progress At A CAGR Of 10.4% By 2033
According to Fact.MR, the global robot vision system market is likely at US$ 2,690.4 million in 2023 and expected to grow at a CAGR of 10.4% during the forecast years of 2023-2033. In order to improve job efficiency and replace human labour, the market for robots is rising and is anticipated to rise more during the coming year. The market is expanding as a result of increased adoption of machine vision
Sales Of Halal Logistics Are Slated To Ascend At A Healthy CAGR Of Close To 9% B …
The most recent analysis from the highly regarded market research consulting company Fact.MR on the worldwide halal logistics industry predicts significant growth through 2021 and beyond. Halal logistics market growth is anticipated to be mostly supported by rising demand for halal food items among the Islamic population within the food & beverage industry for the remainder of the current fiscal year. In the past, the market had significant growth, increasing at
Demand For Cheese Concentrate To Grow At A Positive CAGR Of 10% In Terms Of Valu …
The global cheese concentrate market is anticipated to evolve at a high-value CAGR of 8.8%, rising from its current value of US$ 1.5 billion to US$ 3.5 billion by the end of 2032. In its most recent business intelligence study, Fact.MR depicts the nuts and bolts of the Cheese concentrate market. The Cheese concentrate report provides detailed information on the market's drivers, restraints, opportunities, and trends. Each segment and sub-segment is
01-30-2023 | Health & Medicine
Fact.MR
Sales Of Stretcher Chairs Are Anticipated To Increase At A CAGR Of 4.4% By 2032
Worldwide sales of stretcher chairs are anticipated to increase at a CAGR of 4.4% from 2022 to 2027. The global stretcher chairs market is currently valued at US$ 225.9 million and is estimated to reach a size of US$ 281 million by the end of 2027. The offer in this section includes a variety of opportunities, such as the ability to manufacture goods and provide retail, wholesale, and showcasing services. The

All 5 Releases


More Releases for Antigen

New HGH Saliva Antigen Covid Test gamechanger
An Austrian company HGH Disinfection und Cosmetique Gmbh, based in 9020 Klagenfurt created with a Korean partner a unique antigen salvia test unit which is so simple that anybody can use it. Till now mass testing was nasal stick by government and doctors. Now this new test unit can be used by everybody without a scarry stick in the nose and a result with 95% is ready in 10
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018 |
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1195 Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
ReportsWorldwide has announced the addition of a new report title Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also
CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerT …
ReportsWorldwide has announced the addition of a new report title CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerTestis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
Market Research Hub (MRH) added a new research report to its vast database titled “Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cance …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017”. Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis